TheIndonesia.co - The authorities in Indonesia are yet to approve the use of Convidecia vaccine in the country after the Chinese COVID-19 vaccine get a nod from the World Health Organization, or WHO.
The Indonesian Technical Advisory Group on Immunization (ITAGI) said Convidecia vaccine is not yet included in the national vaccination program because the current supply is still deemed adequate.
“Vaccine [stock] in Indonesia is still adequate, and Convidecia only came a little later,” ITAGI chairperson Sri Rezeki Hadinegoro said on Friday, May 20, as reported by Antara.
She added the vaccine had actually obtained an emergency use authorization (EUA) from the Indonesian Food and Drug Administration, or BPOM, in September 2021, but it has yet to be used in Indonesia as part of the national rollout.
Baca Juga
In Indonesia, vaccines that have been approved for use and included in national program are CoronaVac, COVID-19 Bio Farma, AstraZeneca, Sinopharm, Moderna, Comirnaty (Pfizer and BioNTech), and Janssen vaccines.
On May 19, WHO announced the issuance of emergency use listing (EUL) for Convidecia vaccine, which is developed by Chinese vaccine company CanSino Biologics
WHO explained that the vaccine is “based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2” and that it’s “administered as a single dose”.
“The Technical Advisory Group for Emergency Use Listing, convened by WHO and made up of regulatory experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19 and that the benefits of the vaccine far outweigh risks,” the statement read.
The United Nations organization also confirmed that Convidecia vaccine has been found to have 64 percent efficacy against symptomatic disease and 92 percent against severe COVID-19.
Tag
Terkini
- COIN: Indonesia's First Global Crypto Exchange Ecosystem to Go Public
- COIN Becomes First Crypto Exchange Ecosystem to List on IDX
- A Week After Juliana Marins' Death, Rinjani Claims Another Close Call
- Mount Rinjani: Beauty, Danger, and the Price of Underestimation
- Autopsy of a Climb: Lessons from Juliana Marins' Rinjani Tragedy
- After Tourists Death, Is Mount Rinjanis Trekking Still Safe?
- Juliana's Tragic Fall on Rinjani Sparks Reflection on Mountain Safety
- Driving Visibility: Empowering Women in Formula One and Tech
- Can Whooshs Success Justify a High-Speed Rail to Surabaya?
- Arkadia Digital Media Sees 129% Net Profit Surge in 2024
Berita Terkait
-
Indonesia Eyes End of COVID Restrictions Next Year
-
Health Ministry to Destroy 40.2 Million Expired COVID Vaccine Doses
-
One-Month-Old Baby in Bengkulu Dies After Contracting COVID
-
Indonesia Rolls out Second COVID-19 Booster Shots for Health Workers
-
Smallpox Vaccines Effective Against Monkeypox, Says Health Minister
-
Health Ministry Tightens Surveillance After Monkeypox Declared an Emergency
-
Indonesia Considers 4th COVID Vaccine Dose as Pandemic Fight Continues
-
Booster Jabs Not Urgent for Children: Pediatricians
-
Booster Shots Mandatory for Indonesians Traveling Abroad: Task Force
-
Ministry of Health Calls for Mask-Wearing as COVID Infection Rises